BIONEWS
BINEWS
HCV seroconversion panels supporting early assay development and validation
Early detection remains a key objective in the development of hepatitis C virus (HCV) diagnostic assays. Determining how early antibodies can be detected following infection
BIOMEX at ADLM 2026!
From July 28–30, 2026, BIOMEX will be exhibiting at ADLM 2026 in Anaheim, California. Visit us at Booth #4049 to discover how we help researchers
HIV seroconversion panels: supporting reliable early detection and assay validation
Early detection is one of the most critical performance characteristics of modern HIV diagnostic assays. To accurately evaluate analytical sensitivity and determine how early an
Why high-quality leukopaks matter for reliable immune cell research
Reproducibility remains one of the greatest challenges in immune cell research and cell & gene therapy development. While many factors influence experimental outcomes, one critical
BIOMEX at EACR 2026!
We’re excited to be attending the European Association for Cancer Research (EACR) Congress 2026 in Hashtag#Budapest from June 8–11, 2026! Visit us at Booth #74
Only a few days to go until CIMT 2026!
Only a few days to go until CIMT 2026! At BIOMEX, we support personalized immunotherapy through comprehensive in-house donor characterization and assay capabilities, from immune
BIMEX Journey
#BIOMEXjourney
Always stay up to date. Here we provide news from inside and outside BIOMEX. “Join our Journey” is our campaign on LinkedIn. Here we share progress in tissues, PBMCs and cfDNA – our new market segment for the Life Sciences industry.
Stay connected with BIOMEX and our team on LinkedIn.
Newsletter
Have you already subscribed to our email newsletter?
You will receive more interesting market information and important updates: